|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Renal Cancer - Targeted therapies rapidly take hold of market
Datamonitor, Oct 2007, Pages: 193
In the 7 major markets, we estimate that the incidence of RCC in 2007 will total 86,800 cases.
Around 25% of all RCC patients are diagnosed with Stage IV disease; the 2-year survival rate for these patients is around 23%.
This low survival rate and the fact that a significant proportion of Stage IIII patients relapse with Stage IV disease mean there is significant unmet need in RCC.
Scope
Analysis of RCC market based on a survey of 180 renal cancer specialists, supported by interviews carried out with key opinion leaders
Segmentation of renal cancer patient population by disease subtype, disease stage at presentation and proportion receiving surgery and/or drug therapy
In-depth analysis of treatment patterns in RCC by line of therapy, including most commonly prescribed drug regimens in 7 major markets
Ranking of key prescribing influences in RCC, brand assessment of existing drug therapies, unmet needs and late-phase pipeline overview
Highlights
Pfizers Sutent (sunitinib) is established as the standard-of-care for the first-line treatment of Stage IV RCC in most of the 7 major pharmaceutical markets. Bayer/Onyxs Nexavar (sorafenib) is the most commonly prescribed therapy in the second-line for Sutent-refractory patients. Wyeths Torisel (temsirolimus) will soon be used in some poor-prognosis patients in the first-line and Genentech/Roches Avastin (bevacizumab) may capture some of Sutents first-line market share. Both drugs are also likely to compete for a share of the second-line market in Sutent-refractory patients. Due to high levels of unmet need in renal cancer, there is considerable activity in the late-phase renal cancer pipeline, with 9 drugs in Phase III development including 4 immunotherapies and 5 targeted therapies. The most promising drugs are Novartiss Certican (everolimus) and GlaxoSmithKlines pazopanib.
Reasons to Purchase
Identify key prescribing factors that influence prescription patterns for systemic therapy in renal cancer
Examine the significant unmet need within renal cancer and identify opportunities for new product development
Enhance commercial positioning by increasing understanding of current dynamics within the renal cancer market
Customers who bought this item also bought
Cancer Drug Discoveries: What the Future Holds: Renal Cancer Chapter
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Stakeholder Opinions: Renal Cell Carcinoma - Novel Targeted Treatments to Fill the Void
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Cancer Therapies - Global Strategic Business Report
Drug Delivery Technology - Revolutionizing Cancer Therapies
What's Hot in Cancer Drug R&D?
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Drug Resistance
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Gastric Cancer - Targeted Therapies Compete for First-to-Market Status
|
|
|
|
